Expressions of p53, cyclinD1 and histopathological features in basal cell carcinomas

Journal of Cutaneous Pathology

Volumn 36, Issue 9, 2009, Pages 958-965

  Koseoglu, Resit D ^a   Sezer, Engin ^a   Eyibilen, Ahmet ^a   Aladag, Ibrahim ^a   Etikan, Ilker ^a  

^a GAZIOSMANPASA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; KI 67 ANTIGEN; PROTEIN P53;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; CELL DIFFERENTIATION; CLINICAL ARTICLE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, BASAL CELL; CYCLIN D1; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; SKIN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 68549104276     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/j.1600-0560.2009.01204.x     Document Type: Article

References (57)

1. Chuang TY, Popescu A, Su WP, Chute CG. Basal cell carcinoma. A population-based incidence study in Rochester, Minnesota. J Am Acad Dermatol 1990 22: 413.
2. Parkin DM, Muir CS. Cancer incidence in five continents. Comparability and quality of data. IARC Sci Publ 1992 120: 45.
3. Staples M, Marks R, Giles G. Trends in the incidence of non-melanocytic skin cancer (NMSC) treated in Australia 1985-1995: are primary prevention programs starting to have an effect? Int J Cancer 1998 78: 144.
4. Plesko I, Severi G, Obsitnikova A, Boyle P. Trends in the incidence of non-melanoma skin cancer in Slovakia, 1978-1995. Neoplasma 2000 47: 137.
5. Miller DL, Weinstock MA. Nonmelanoma skin cancer in the United States: incidence. J Am Acad Dermatol 1994 30: 774.
6. Coebergh JW, Neumann HA, Vrints LW, van der Heijden L, Meijer WJ, Verhagen Teulings MT. Trends in the incidence of non-melanoma skin cancer in the SE Netherlands 1975-1988: a registry-based study. Br J Dermatol 1991 125: 353.
7. Zagrodnik B, Kempf W, Seifert B, et al. Superficial radiotherapy for patients with basal cell carcinoma. Cancer 2003 98: 2708.
8. Auepemkiate S, Boonyaphiphat P, Thongsuksaip P. 53 expression related to the aggressive infiltrative histopathological feature of basal cell carcinoma. Histopathology 2002 40: 568.
9. Safai B, Good RA. Basal cell carcinoma with metastasis: review of literature. Arch Pathol Lab Med 1977 101: 237.
10. Rowe DE, Carroll RJ, Day CL Jr. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implication for patient follow-up. J Dermatol Surg Oncol 1989 15: 315.
11. Cernea CR, Ferraz AR, Castro IV, et al. p53 and skin carcinomas with skull base invasion: a case-control study. Otolaryngology Head Neck Surg 2006 134: 471.
12. Staibano S, Lo Muzio L, Pannone G, et al. DNA ploidy and cyclin D1 expression in basal cell carcinoma of the head and neck. Am J Clin Pathol 2001 115: 805.
13. Stratigos AJ, Kapranos N, Petrakou E, et al. Immunophenotypic analysis of the p53 gene in non-melanoma skin cancer and correlation with apoptosis and cell proliferation. J Eur Acad Dermatol Venereol 2005 19: 180.
14. Ansarin H, Daliri M, Soltani-Arabshahi R. Expression of p53 in aggressive and non-aggressive histologic variants of basal cell carcinoma. Eur J Dermatol 2006 16: 543.
15. McNutt NS, Saenz SC, Volkenandt M, Shea CR, Albino AP. Editorial review. Abnormalities of p53 protein expression in cutaneous disorders. Arch Dermatol 1994 130: 225.
16. Kerschmann RL, McCalmont TH, LeBoit PE. p53 oncoprotein expression and proliferation index in keratoacanthoma and squamous cell carcinoma. Arch Dermatol 1994 130: 181.
17. Gusterson BA, Anbazhagan R, Warren W, et al. Expression of p53 in premalignant and malignant squamous epithelium. Oncogene 1991 6: 1785.
18. Ouhtit A, Nakazawa H, Armstrong BK, et al. UV-radiation-specific p53 mutation frequency in normal skin as a predictor of risk of basal cell carcinoma. J Natl Cancer Inst 1998 90: 523.
19. Ziegler A, Leffell DJ, Kunala S, et al. Mutation hotspots due to sunlight in the p53 gene of nonmelanoma skin cancers. Proc Natl Acad Sci U S A 1993 90: 4216.
20. Ro YS, Cooper PN, Lee JA, et al. p53 protein expression in benign and malignant skin tumor. Br J Dermatol 1993 128: 237.
21. Shea CR, McNutt NS, Volkenandt M, Lugo J, Prioleau PG, Albino AP. Overexpression of p53 protein in basal cell carcinoma of human skin. Am J Pathol 1992 141: 25.
22. McGregor JM, Yu CCW, Dublin EA, Levison DA, MacDonald DM. Aberrant expression of p53 tumour-suppressor protein in nonmelanoma skin cancer. Br J Dermatol 1992 127: 463.
23. Barbareschi M, Girlando S, Cristofolini P, Cristofolini M, Togni R, Boi S. p53 protein expression in basal cell carcinoma. Histopathology 1992 21: 579.
24. Barrett TL, Smith KJ, Hodge JJ, Butter R, Hall FW, Skelton HG. Immunohistochemical nuclear staining for p53, PCNA, and Ki-67 in different histologic variants of basal cell carcinoma. J Am Acad Dermatol 1997 37: 430.
25. De Rosa G, Staibano S, Barra E, et al. p53 protein in aggressive and non-aggressive basal cell carcinoma. J Cutan Pathol 1993 20: 429.
26. Healy E, Angus B, Lawrence CM, Rees JL. Prognostic value of Ki67 antigen expression in basal cell carcinomas. Br J Dermatol 1995 133: 737.
27. Brown DC, Gatter KC. Monoclonal antibody Ki-67: its use in histopathology. Histopathology 1990 17: 489.
28. Ueda T, Aozasa K, Tsujimoto M, et al. Prognostic significance of Ki-67 reactivity in soft tissue sarcomas. Cancer 1989 63: 1607.
29. Hall M, Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res 1996 68: 67.
30. Bosch F, Jares P, Campo E, et al. PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. Blood 1994 84: 2726.
31. Soini Y, Kamel D, Paakko P, Lehto VP, Oikarinen A, Vahakangas K. Aberrant accumulation of p53 associates with Ki67 and mitotic count in benign skin lesions. Br J Dermatol 1994 131: 514.
32. Abdelsayed RA, Guijarro-Rojas M, Ibrahim NA, Sangueza OP. Immunohistochemical evaluation of basal cell carcinoma and trichepithelioma using Bcl-2, Ki67, PCNA and P53. J Cutan Pathol 2000 27: 169.
33. Urano Y, Asano T, Yoshimoto K, et al. Frequent p53 accumulation in the chronically sun-exposed epidermis and clonal expansion of p53 mutant cells in the epidermis adjacent to basal cell carcinoma. J Invest Dermatol 1995 104: 928.
34. Boonchai W, Walsh M, Cummings M, Chenevix Trench G. Expression of p53 in arsenic-related and sporadic basal cell carcinoma. Arch Dermatol 2000 136: 195.
35. Backvall H, Wolf O, Hermelin H, Weitzberg E, Ponten F. The density of epidermal p53 clones is higher adjacent to squamous cell carcinoma in comparison with basal cell carcinoma. Br J Dermatol 2004 150: 259.
36. Brash DE, Rudolph JA, Simon JA, et al. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci U S A 1991 88: 10124.
37. Pontén F, Berg C, Ahmadian A, et al. Molecular pathology in basal cell cancer with p53 as a genetic marker. Oncogene 1997 15: 1059.
38. Ren ZP, Hedrum A, Pontén F, et al. Human epidermal cancer and accompanying precursors have identical p53 mutations different from p53 mutations in adjacent areas of clonally expanded nonneoplastic keratinocytes. Oncogene 1996 12: 765.
39. Ziegler A, Jonason AS, Leffell DJ, et al. Sunburn and p53 in the onset of skin cancer. Nature 1994 372: 773.
40. Park HR, Min SK, Cho HD, Kim KH, Shin HS, Park YE. Expression profiles of p63, p53, survivin, and hTERT in skin tumors. J Cutan Pathol 2004 31: 544.
41. Chang CH, Tsai RK, Chen GS, Yu HS, Chai CY. Expression of bcl-2, p53 and Ki-67 in arsenical skin cancers. J Cutan Pathol 1998 25: 457.
42. Sutter C, Wersin R, Varnai M, Friemann J. Elevated p53 protein expression in normal and neoplastic light-exposed epidermis. Verh Dtsch Ges Pathol 1994 78: 246.
43. Khorsid SM, Glover MT, Churchill L, McGregor JM, Proby CM. p53 immunoreactivity in non-melanoma skin cancer from immunosuppressed and immunocompetent individuals: a comparative study of 246 tumours. J Cutan Pathol 1996 23: 229.
44. Wikonkal NM, Brash DE. Ultraviolet radiation induced signature mutations in photocarcinogenesis. J Invest Dermatol Symp Proc 1999 4: 6.
45. Robles AI, Conti CJ. Early overexpression of cyclin D1 protein in mouse skin carcinogenesis. Carcinogenesis 1995 16: 781.
46. Zhang SY, Liu SC, Goodrow T, Morris R, Klein-Szanto AJ. Increased expression of G1 cyclins and cyclin-dependent kinases during tumor progression of chemically induced mouse skin neoplasms. Mol Carcinog 1997 18: 142.
47. Liang SB, Furihata M, Takeuchi T, et al. Overexpression of cyclin D1 in nonmelanocytic skin cancer. Virchows Arch 2000 436: 370.
48. Bolshakov S, Walker CM, Strom SS, et al. p53 mutations in human aggressive and nonaggressive basal and squamous cell carcinomas. Clin Cancer Res 2003 9: 228.
49. Sexton M, Jones DB, Maloney ME. Histologic pattern analysis of basal cell carcinoma. Study of a series of 1039 consecutive neoplasms. J Am Acad Dermatol 1990 23: 1118.
50. Rippey JJ, Rippey E. Characteristics of incompletely excised basal cell carcinomas of the skin. Med J Aust 1997 166: 581.
51. Kim KH, Park EJ, Seo YJ, et al. Immunohistochemical study of cyclooxygenase-2 and p53 expression in skin tumors. J Dermatol 2006 33: 319.
52. Dixon AY, Lee SH, McGregor DH. Factors predictive of recurrence of basal cell carcinomas. Am J Dermatopathol 1989 11: 222.
53. Gimenez-Conti IB, Collet AM, Lanfranchi H, et al. p53, Rb, and cyclin D1 expression in human oral verrucous carcinomas. Cancer 1996 78: 17.
54. Gillett C, Fand V, Smith R, et al. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 1994 54: 1812.
55. Chetty R, Chetty S. Cyclin D1 and retinoblastoma protein expression in oesophageal squamous cell carcinoma. Mol Pathol 1997 50: 257.
56. Schauer IE, Siriwardana S, Langan TA, Sclafani RA. Cyclin D1 overexpression vs. retinoblastoma inactivation: implications for growth control evasion in non-small cell and small cell lung cancer. Proc Natl Acad Sci U S A 1994 91: 7827.
57. Arber N, Hibshoosh H, Moss SF, et al. Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. Gastroenterology 1996 110: 669.